ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE

BACKGROUND: Current therapies for recurrent glioblastoma provide limited survival benefit. In the open-label, phase 3 CheckMate 143 study (NCT02017717), although the primary endpoint was not met, the median overall survival (mOS) was comparable between nivolumab (anti–PD-1) and bevacizumab in the ov...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Weller, Michael, Reardon, David, Brandes, Alba, Sampson, John, Mulholland, Paul, Wick, Antje, Baehring, Joachim, Ahluwalia, Manmeet, Roth, Patrick, Bähr, Oliver, Phuphanich, Surasak, Sepulveda, Juan, de Souza, Paul, Sahebjam, Solmaz, Potter, Von, Tatsuoka, Kay, Taitt, Corina, Zwirtes, Ricardo, Omuro, Antonio, Lim, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Adult Clinical Trials–Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847600/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.045
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados